Looking into the eye of ADHD.

Looking into the eye of ADHD. Investigating the relationship between ADHD, the delayed circadian rhythm and the functioning of the eye.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON22441

Enrollment

Registered

2013-12-24

Start date

2015-02-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention-deficit/hyperactivity disorder (ADHD)

Interventions

A 3-week intervention of one of the following: 1A) Methylphenidate, 3 x 20 mg/day 1B) Placebo, 3 x 20mg/day 2A) Light Therapy, 30 minutes/day 2B) Waiting list 3A) Mel, 3 mg/day 3B) Placebo, 3 m

Eligibility

Inclusion criteria

Inclusion criteria: Patient group and control group: Age 18 to 40 years old. Patient group: Diagnosis of ADHD.

Exclusion criteria

Exclusion criteria: Patient group and control group: Severe psychiatric comorbidity; substance abuse; contraindication for the intervention. Control group: ADHD; use of stimulant medication.

Design outcomes

Primary

Measure	Time frame
The change in Post-Illumination Pupil Response (PIPR).	—

Secondary

Measure	Time frame
- A change in refractive error test for myopia (nearsightedness), hyperopia (farsightedness), astigmatism (cylindrical error), presbyopia (focus difficulty), and strabismus (alignedness of the eyes); - A change in colour discrimination ability; - A change in oculomotor functioning; - A change in perimetry score (visual field); - A change in the self-reported oversensitivity to light. - A change in the self-reported ADHD symptoms on the ADHD Rating Scale (ADHD-RS); - A change in the performance on the QbTest, which measures ADHD symptoms objectively; - A change in Dim-Light Melatonin Onset (DLMO); - A change in chronotype as measured by the Munich Chronotype Questionnaire (MCTQ); - A change in chronotype as measured by the Morningness-Eveningness Questionnaire (MEQ); - A change in fatigue as measured by the Multidimensional Assessment of Fatigue (MAF); - A change on the Seasonal Pattern Assessment Questionnaire (SPAQ).	—

Measure

Time frame

- A change in refractive error test for myopia (nearsightedness), hyperopia (farsightedness), astigmatism (cylindrical error), presbyopia (focus difficulty), and strabismus (alignedness of the eyes); - A change in colour discrimination ability; - A change in oculomotor functioning; - A change in perimetry score (visual field); - A change in the self-reported oversensitivity to light. - A change in the self-reported ADHD symptoms on the ADHD Rating Scale (ADHD-RS); - A change in the performance on the QbTest, which measures ADHD symptoms objectively; - A change in Dim-Light Melatonin Onset (DLMO); - A change in chronotype as measured by the Munich Chronotype Questionnaire (MCTQ); - A change in chronotype as measured by the Morningness-Eveningness Questionnaire (MEQ); - A change in fatigue as measured by the Multidimensional Assessment of Fatigue (MAF); - A change on the Seasonal Pattern Assessment Questionnaire (SPAQ).

—

Contacts

Public ContactDenise Bijlenga

PsyQ Psycho-Medical Programs, Expertise Center Adult ADHD, The Hague

dbijlenga@sein.nl+31-(0)88 357 3076

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)